Cytokinetics (CYTK)
Developer of muscle-directed medicines led by MYQORZO for hypertrophic cardiomyopathy.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 127.53% | 158.70M shares | |
|---|---|---|---|
| 512 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.76% | 942.2K shares | |
| 16 holders · as of Sep 15, 2026 | |||
| Adds to | 128.29% | ||
124.43M company shares as of Aug 28, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (139.02M in the company's Sep 22, 2026 report, 124.43M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 128.29%; nothing is left for Other.
13F, as of Jun 30, 2026
512 holders · 158.70M shares · 93 new positions · 335 increased · 105 reduced · 55 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 20.09M | 16.15% | +3.55M | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | 18.72M | 15.04% | +1.19M | Aug 14, 2026 |
| Wellington Management Group LLP | 6.93M | 5.57% | −1.08M | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 6.71M | 5.39% | +868.0K | Aug 13, 2026 |
| State Street Corp | 6.49M | 5.22% | +749.0K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 6.12M | 4.92% | +628.9K | Aug 13, 2026 |
| FMR LLC | 5.03M | 4.04% | −5.69M | Aug 13, 2026 |
| Avoro Capital Advisors LLC | 5.00M | 4.02% | +1.67M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 14.50% | 17.72M | 13G | Feb 17, 2026 |
| BlackRock, Inc. | 13.00% | 15.25M | Oct 23, 2024 | |
| FMR LLC | 9.00% | 11.14M | 13G | May 6, 2026 |
| Vanguard Capital Management | 5.21% | 6.42M | 13G | Apr 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | Robert I. Blumdirector, officer: President & CEO | Sale | 97,926 | $69.33 | 0 |
| Sep 14, 2026 | Robert I. Blumdirector, officer: President & CEO | Sale | 7,500 | $73.44 | 377,820 |
| Sep 15, 2026 | Robert E. Landrydirector | Sale | 1,000 | $72.13 | 8,184 |
| Sep 11, 2026 | Robert E. Landrydirector | Sale | 1,000 | $74.66 | 9,184 |
| Sep 8, 2026 | Fady Ibraham Malikofficer: EVP Research & Development | Sale | 3,500 | $75.46 | 153,902 |
| Sep 1, 2026 | B. Lynne Parshalldirector | Sale | 5,000 | $71.48 | 10,784 |
| Aug 31, 2026 | Robert I. Blumdirector, officer: President & CEO | Sale | 7,500 | $70.24 | 377,820 |
| Aug 31, 2026 | Andrew Callosofficer: EVP, Chief Commercial Officer | Sale | 10,000 | $70.24 | 58,555 |
| Aug 18, 2026 | Fady Ibraham Malikofficer: EVP Research & Development | Sale | 3,500 | $75.82 | 153,902 |
| Aug 10, 2026 | Robert I. Blumdirector, officer: President & CEO | Sale | 7,500 | $76.76 | 377,820 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Gilbert Cisneros · CA31 | Purchase | $1,001 – $15,000 | Jun 30, 2026 | Jul 3, 2026 |